Eli Lilly (NYSE:LLY) just grew revenue 55.5% in a single quarter while raising full-year guidance to $82 billion to $85 billion. Mounjaro and Zepbound combined for $12.8 billion in Q1 alone. Yet ...

This is the most decisive dimension in the comparison. Lilly’s GLP-1 franchise is generating revenue growth that almost no large-cap company has ever sustained at this scale. Full-year 2025 revenue ...

In the first quarter, Eli Lilly's revenue of $19.8 billion grew by 56% year over year. Top-line growth rates of this caliber are exceedingly rare for major pharmaceutical companies, but not so much ...

Shares of Eli Lilly (LLY) added ~6% in the premarket on Thursday after the Indiana-based pharma giant raised its full-year outlook alongside better-than-expected Q1 2026 financials driven by its GLP-1 ...

Lilly's GLP-1 drugs Mounjaro and Zepbound drive revenue growth International sales of Mounjaro help extend Lilly's marker lead Investors eye Foundayo's US launch as test for future obesity-drug market ...

With the recent launches of Novo Nordisk’s Wegovy pill and Eli Lilly’s Foundayo, the obesity market has started to shift toward oral GLP-1 drugs. While Novo leverages its first-mover advantage with ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now. There’s been huge hype around AI’s potential for drug discovery. But at Eli Lilly, ...

(Reuters) -Eli Lilly raised its full-year profit and revenue forecast on Thursday, betting on surging demand for its blockbuster GLP-1 drugs. The company said it expects to earn $23.00 to $23.70 per ...

Both Novo Nordisk and Eli Lilly are grappling with pricing pressure in the U.S., but their 2026 outlooks are diverging sharply. While Novo is bracing for a sales decline, Lilly sees revenue charging ...